
Tarsus Pharmaceuticals
(NASDAQ) TARS
Tarsus Pharmaceuticals Financials at a Glance
Market Cap
$2.77B
Revenue (TTM)
$535.08M
Net Income (TTM)
-$48.27M
EPS (TTM)
-$1.13
P/E Ratio
-56.77
Dividend
$0.00
Beta (Volatility)
0.90 (Low)
Dividend
$0.00
Beta (Volatility)
0.90 (Low)
Price
$62.88
Volume
31,864
Open
$64.69
Price
$62.88
Volume
31,864
Open
$64.69
Previous Close
$62.88
Daily Range
$60.89 - $66.49
52-Week Range
$38.51 - $85.25
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
0.90 (Low)
Price
$62.88
Volume
31,864
Open
$64.69
Previous Close
$62.88
Daily Range
$60.89 - $66.49
52-Week Range
$38.51 - $85.25
Estimated Earnings Date
Aug 6, 2026
TARS News
TARS: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Tarsus Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
370
CEO
Bobak Azamian, MD, PhD
Website
tarsusrx.comHeadquarters
Irvine, CA 92618, US
TARS Financials
Key Financial Metrics (TTM)
Gross Margin
90.44%
Operating Margin
-9.50%
Net Income Margin
-9.02%
Return on Equity
-14.19%
Return on Capital
-16.24%
Return on Assets
-8.31%
Earnings Yield
-1.76%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.77B
Shares Outstanding
43.02M
Volume
31.86K
Avg. Volume
633.84K
Financials (TTM)
Gross Profit
$483.93M
Operating Income
-$50.81M
EBITDA
-$40.18M
Operating Cash Flow
-$16.45M
Capital Expenditure
-$15.09M
Free Cash Flow
-$31.54M
Cash & ST Invst.
$388.73M
Total Debt
$88.68M
Tarsus Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$162.05M
+106.9%
Gross Profit
$152.66M
+108.8%
Gross Margin
94.20%
N/A
Market Cap
$2.77B
N/A
Market Cap/Employee
$8.57M
N/A
Employees
323
N/A
Net Income
-$6.97M
+72.3%
EBITDA
-$6.75M
+69.9%
Quarterly Fundamentals
Total Cash
$388.73M
-4.7%
Total Debt
$88.68M
+22.5%
Accounts Receivable
$117.21M
+82.7%
Inventory
$4.57M
+69.0%
Long Term Debt
$88.68M
+23.2%
Short Term Debt
$0.00
-100.0%
Return on Assets
-8.31%
N/A
Return on Invested Capital
-11.61%
N/A
Free Cash Flow
-$30.47M
-43.4%
Operating Cash Flow
-$24.65M
-19.4%

